Patient disposition. ∗Reasons for exclusion are listed in supplemental Table 5. †Five patients who were randomized to the once-weekly KRd56 group and did not receive a dose of 56 mg/m² were included in the twice-weekly KRd27 group for safety analysis. ‡The primary reason for discontinuing carfilzomib/dexamethasone included adverse event, death, and patient request. §The primary reason for discontinuing lenalidomide included adverse event and patient request.